Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:CRDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.19+3.3%$3.42$2.56▼$7.73$414.37M0.184.54 million shs515,491 shsCRDLCardiol Therapeutics$1.37+3.4%$1.23$0.88▼$1.71$152.63M0.77574,085 shs100,059 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%+9.57%-4.63%-34.12%-44.72%CRDLCardiol Therapeutics0.00%-3.65%-4.35%+24.53%+14.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.19+3.3%$3.42$2.56▼$7.73$414.37M0.184.54 million shs515,491 shsCRDLCardiol Therapeutics$1.37+3.4%$1.23$0.88▼$1.71$152.63M0.77574,085 shs100,059 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%+9.57%-4.63%-34.12%-44.72%CRDLCardiol Therapeutics0.00%-3.65%-4.35%+24.53%+14.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.50Moderate Buy$18.00463.73% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50522.71% UpsideCurrent Analyst Ratings BreakdownLatest CHSS, ALT, CRDL, and ESYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/27/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026ALTAltimmune Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.003/16/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $25.003/6/2026ALTAltimmune B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $13.003/5/2026ALTAltimmune William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 5/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K10,385.23N/AN/A$1.99 per share1.60CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$1.01N/AN/AN/A-214,860.98%-49.35%-41.65%5/13/2026 (Estimated)CRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-239.10%-165.77%5/13/2026 (Estimated)Latest CHSS, ALT, CRDL, and ESYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALTAltimmune-$0.25N/AN/AN/A$0.00 millionN/A5/13/2026Q1 2026CRDLCardiol Therapeutics-$0.07N/AN/AN/AN/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/A3/5/2026Q4 2025ALTAltimmune-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1518.5518.55CRDLCardiol TherapeuticsN/A4.164.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CRDLCardiol Therapeutics12.49%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%CRDLCardiol Therapeutics5.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50130.10 million128.02 millionOptionableCRDLCardiol Therapeutics20111.82 million105.95 millionNot OptionableCHSS, ALT, CRDL, and ESYS HeadlinesRecent News About These CompaniesCardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on WednesdayMay 11 at 3:51 AM | americanbankingnews.comCardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart AssociationMay 7, 2026 | prnewswire.comCardiol Therapeutics (CRDL) Projected to Post Earnings on WednesdayMay 6, 2026 | marketbeat.comCardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal ProgramApril 28, 2026 | prnewswire.comCardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis PromiseApril 15, 2026 | marketbeat.comCardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartApril 14, 2026 | finanznachrichten.deCardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live InterviewApril 14, 2026 | tipranks.comCardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartApril 14, 2026 | newsfilecorp.comNCardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of ShareholdersApril 10, 2026 | tipranks.comCardiol Therapeutics Announces Year-End 2025 Update on OperationsApril 1, 2026 | newsfilecorp.comNWhy Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 7.22%March 30, 2026 | aaii.comACardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care ConferenceFebruary 25, 2026 | tipranks.comCardiol Therapeutics to Present at TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | newsfilecorp.comNCardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart FailureFebruary 10, 2026 | tipranks.comCardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart FailureFebruary 10, 2026 | newsfilecorp.comNCardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 MillionJanuary 23, 2026 | newsfilecorp.comNTop Canadian Stocks to Buy Right Away With $5,000January 21, 2026 | msn.comCardiol Therapeutics Inc.: Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 MillionJanuary 16, 2026 | finanznachrichten.deCardiol Therapeutics announces $13.5M bought-deal private placementJanuary 16, 2026 | msn.comCardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 MillionJanuary 16, 2026 | newsfilecorp.comNCardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 MillionJanuary 16, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026This 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson | April 20, 2026The $880M Bet to Survive Real Estate's ResetBy Jeffrey Neal Johnson | April 28, 2026A Quiet Outperformer With a Catastrophe CaveatBy Peter Frank | April 14, 2026CHSS, ALT, CRDL, and ESYS Company DescriptionsAltimmune NASDAQ:ALT$3.19 +0.10 (+3.33%) As of 10:45 AM Eastern This is a fair market value price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Cardiol Therapeutics NASDAQ:CRDL$1.36 +0.05 (+3.41%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tapestry Stock Drops After Strong Quarter and Raised Outlook MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance The Stars Are Aligning For Apple: Get Ready for $300 3 Under-The-Radar Small Caps Making New All-Time Highs Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
